Profile cover photo
Profile photo
Advaxis, Inc.
34 followers -
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.

34 followers
About
Posts

Post is pinned.Post has attachment
Our Lm Technology™ utilizes the efficiency of the entire immune system by teaching it to recognize the tumor as a threat, and by weakening the tumor’s defenses. Once educated by Lm Technology™, the immune system—specifically, its killer T cells—are enabled to do their job and work to destroy the cancer. http://www.advaxis.com/lm-technology/
Photo

Post has attachment
Advaxis is pleased to announce that the combination trial with Merck has completed the first two dose-escalation cohorts, and the study evaluating ADXS-PSA has launched the third cohort. Read the full announcement here:

Post has attachment
Advaxis is scheduled to present key milestones and company initiatives at the 3rd Annual Jefferies Immuno-Oncology Summit on April 8. Read the full announcement here: 

Post has attachment
Advaxis has announced the completion of the first dose-escalation cohort in their combination trial with MedImmune, and has commenced the second dose-escalation cohort. Read the full announcement here: 

Post has attachment
We are pleased to announce that Advaxis has elected Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors. Read the full announcement here:

Post has attachment
Advaxis announced today that Gregory Mayes, Executive Vice President and Chief Operating Officer, will present at the 27th annual ROTH Capital Partners Conference. Read the full announcement here: 

Post has attachment
Advaxis is pleased to announce that our Phase 2 study in head and neck cancer has been selected as a late-breaker poster presentation at the American Association for Cancer Research Annual Meeting. Read the full announcement here: 

Post has attachment
Advaxis announces CEO Daniel J. O'Connor will present at the Cowen and Company 36th Annual Health Care Conference on March 9. Read the full announcement here: 

Post has attachment
Photo

Post has attachment
Advaxis is collaborating with the Farrah Fawcett Foundation to develop drugs for HPV-associated anal cancers. Learn more here:
Wait while more posts are being loaded